Team
TXN Systems is a growing organisation, supported by an expert advisory board, dedicated to the development of EbsArgent as a new solution to antimicrobial resistance.
TEAM MEMBERS
Prof. Elias S.J. Arnér, MD PhD
CEO
ea@txnsystems.com
A world-renowned scientist in redox biology and biotechnological applications with more than 170 publications and four granted patents, who succeeded Prof. Arne Holmgren as head of the Division of Biochemistry at MBB, Karolinska Institutet. Elias has effectively translated his successful academic research into commercial ventures within biotechnology and medicine, bridging scientific ingenuity with real-world impact. Through astute leadership and exceptional business intelligence he has promoted fast-paced technology development and efficient market entry of several companies, fostering innovation.
Mohamad Takwa, PhD
Business Advisor
mt@txnsystems.com
With a PhD in Biotechnology and 20 years of experience in the life sciences field, he has built a track record of translating cutting-edge science into products and companies. He has co-founded, led and exited multiple biotech and MedTech ventures. His expertise spans integrating innovation with business strategy, driving complex projects to success, and fostering cross-disciplinary collaborations. His contributions to diagnostics, therapeutics, and industrial biotechnology have consistently delivered high-impact solutions.
Carlos Ratia Loncán, PhD
CTO
cr@txnsystems.com
A clinical microbiologist with a PhD from the University of Barcelona where his primary research focused on novel antibiotics targeting multidrug-resistant pathogens. Carlos has also specifically explored metalloantibiotics as inhibitors of the bacterial thioredoxin system. His expertise encompasses resistance mechanisms and antibacterial efficacy across various conditions, coupled with comprehensive experience in designing and analysing in-vivo studies.
Isak Edvardsson
Business Developer & Administrator
ie@txnsystems.com
A business developer with a degree in financing from Lund University School of Economics and Management. Isak has diverse and valuable experience from working in several early-stage innovative ventures, bringing his expertise in business administration to support their growth and success. He believes in the power of start-ups and SMEs to drive innovation and societal beneficial change.
EXTERNAL ADVISORS
Mikael Thomsen, PhD
External advisor
An expert drug developer with more than 25 years’ experience from the pharmaceutical industry. Mikael has a PhD in pharmacology & toxicology and has worked at Novartis Pharma, Novo Nordisk and various European biotech companies where he held roles such as Chief Development Officer, CSO and Head of R&D. He also co-founded several biotech companies himself and has worked for the U.S. Food and Drug Administration (FDA).
Helen Steel, MD
External advisor
A pharmaceutical industry expert with extensive experience in infectious diseases R&D. Was a Director of Clinical Development at GlaxoSmithKline for 15 years, and later became the Head Unit Physician for the Infectious Diseases Therapeutic Area. Helen has led a global team of pharmacovigilance professionals in her position as Head of Shared Safety Sciences and has nearly 30 years’ experience in the pharmaceutical development industry.
